Ascendis Pharma A/S (NASDAQ:ASND) Hits New 12-Month High – Still a Buy?

Ascendis Pharma A/S (NASDAQ:ASND)’s stock price hit a new 52-week high during trading on Monday . The company traded as high as $168.74 and last traded at $167.04, with a volume of 130347 shares traded. The stock had previously closed at $152.98.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Cantor Fitzgerald lifted their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 25th. UBS Group began coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price target for the company. Evercore ISI boosted their price objective on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a research report on Tuesday, February 18th. Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Ascendis Pharma A/S from $167.00 to $168.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $202.36.

Ascendis Pharma A/S Stock Performance

The firm has a market capitalization of $9.95 billion, a P/E ratio of -23.10 and a beta of 0.62. The business’s fifty day moving average price is $138.31 and its two-hundred day moving average price is $134.68.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. Sell-side analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth $174,000. Woodline Partners LP increased its holdings in Ascendis Pharma A/S by 35.2% during the 4th quarter. Woodline Partners LP now owns 317,642 shares of the biotechnology company’s stock worth $43,730,000 after purchasing an additional 82,624 shares during the period. Zimmer Partners LP raised its holdings in Ascendis Pharma A/S by 24.2% in the fourth quarter. Zimmer Partners LP now owns 96,900 shares of the biotechnology company’s stock valued at $13,340,000 after acquiring an additional 18,900 shares in the last quarter. Vestal Point Capital LP lifted its position in shares of Ascendis Pharma A/S by 108.0% during the 4th quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company’s stock worth $71,588,000 after purchasing an additional 270,000 shares during the last quarter. Finally, Soleus Capital Management L.P. acquired a new position in Ascendis Pharma A/S in the fourth quarter valued at approximately $19,824,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.